Mar 08, 2023 / 03:30PM GMT
Philip M. Nadeau - TD Cowen, Research Division - MD & Senior Research Analyst
TD Cowen's 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to do a fireside chat with BioMarin Pharmaceutical. Those of you who follow our research know that BioMarin is one of our top picks for this year. We think it's 18% revenue CAGR over the next several years is one of the highlights of the profitable biotech industry. So we're really happy to have with us today Brian Mueller, the Executive Vice President and CFO; Traci McCarty is also here in the front row.
Brian, we'll start maybe just handing it to you in terms of the corporate outlook. Can you give us a state of the company overview, biggest strength, biggest challenges, what does BioMarin need to do to create shareholder value over the next couple of years?
Brian R. Mueller - BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO
Yes. Thanks a lot, Phil. Thanks for having us and the opportunity to catch up today. We've had an eventful week
Biomarin Pharmaceutical Inc at Cowen Health Care Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers